- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01458288
A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
Stony Brook, New York, United States, 11794
- Stony Brook University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female 18 to 75 years of age inclusive;
- Patients with confirmed pathology diagnosis of MM, NHL or HD;
- Potential candidate for autologous stem cell transplantation at Investigator's discretion;
- 4 weeks since last cycle of chemotherapy prior to the study drug administration;
- Total dose of melphalan received 200 mg in the most recent chemotherapy treatment;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- Recovered from all acute toxic effects of prior chemotherapy at Investigator's discretion;
- White blood cell (WBC) count 3.0 x 109/L on screening laboratory assessments;
- Absolute neutrophil count 1.5 x 109/L on screening laboratory assessments;
- Platelet count 100 x 109/L on screening laboratory assessments;
- Serum creatinine 2.2 mg/dL on screening laboratory assessments;
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin < 2 x upper limit of normal (ULN) on screening laboratory assessments;
- Negative for human immunodeficiency virus (HIV);
- Adequate cardiac and pulmonary function to undergo leukapheresis at Investigator's discretion;
For females, one of the following criteria must be fulfilled:
- At least one year post-menopausal, or
- Surgically sterile, or
- Willing to use a double-barrier method [intrauterine device (IUD) plus condom, spermicidal gel plus condom] of contraception from study Day 1 until 28 days after the last dose of TG-0054;
- Males must be willing to use a reliable form of contraception (use of a condom or a partner fulfilling the above criteria) from study Day 1 until 28 days after the last dose of TG-0054;
- Able to provide the signed informed consent.
Exclusion Criteria:
- Received radiation therapy to the pelvis;
- Received > 6 cycles of lenalidomide;
- Evidence of bone marrow involvement of lymphoma in NHL patients;
- Failed previous stem cell collection [failed to collect 2 x 106 CD34+ cells/kg within 4 leukapheresis sessions after receiving granulocyte colony-stimulating factor (G-CSF)];
- Patients who have undergone previous stem cell transplantation procedure;
- Received G-CSF within 2 weeks prior to the study drug administration;
- History of other cancer within the past 5 years excluding MM, NHL, HD, basal cell or squamous cell carcinoma of the skin;
- History of other hematologic disorders including bleeding or thromboembolic disease being treated with anti-coagulant;
- History of poor and uncontrollable cardiovascular or pulmonary disease such as myocardial infarction, cardiac arrhythmias, transient ischemic attack, stroke or Chronic Obstructive Pulmonary Disease (COPD) patients hospitalized more than two times a year due to underlying disease;
- Diagnosis of sickle cell anemia or documented sickle cell trait;
- Patients with proliferative retinopathy;
- Uncontrollable malignancy with MM, NHL or HD, or carcinomatous meningitis, at Investigator's discretion;
- Any infection required antibiotic treatment or unexplained fever above 38 °C within 3 days prior to dosing;
- Pregnant or breast-feeding;
- Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study;
- Received any other investigational drug within 1 month before entering the study;
- Received prior treatment with TG-0054 but withdrew early from this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: TG-0054 (3.14 mg/kg)
|
3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg
Time Frame: 1 week
|
Patients were all with multiple myeloma (MM), Non-Hodgkin lymphoma (NHL) or Hodgkin disease (HD). Number of patients who mobilized the targeted total number of CD34+ cells within a maximum of 4 leukapheresis sessions in study arm 1 and arm 3. Patients in arm 1 followed administration of TG-0054 (3.14 mg/kg) alone and leukapheresis start from study day 1. Patients in arm 3 followed administration of TG-0054 (3.14 mg/kg) combined with granulocyte colony-stimulating factor (G-CSF) and leukapheresis start from study day 8. |
1 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the Average Number of Leukapheresis Sessions
Time Frame: 1 week
|
To determine the average number of leukapheresis sessions required to collect 2.5 x10^6 CD34+ cells/kg.
|
1 week
|
Circulating CD34+ Cell Count in Peripheral Blood
Time Frame: pre-dose(-2 to 0 h),2, 4 and 6 hr after dosing.
|
Calculate the median total CD34+ cell counts across all leukapheresis sessions following TG 0054 administration alone and in combination with G-CSF mobilization in order to evaluate the pharmacodynamics (PD) of TG-0054 by determining circulating CD34+ cell counts in peripheral blood.
|
pre-dose(-2 to 0 h),2, 4 and 6 hr after dosing.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael W. Schuster, M.D., Stony Brook University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Lymphoma
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Hodgkin Disease
- Lymphoma, Non-Hodgkin
Other Study ID Numbers
- TG-0054-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on TG-0054
-
GPCR Therapeutics, Inc.CompletedMultiple Myeloma | Hodgkin Disease | Non-Hodgkin LymphomaTaiwan
-
GPCR Therapeutics, Inc.Completed
-
GPCR Therapeutics, Inc.CompletedMultiple Myeloma | Hodgkin Disease | Non-Hodgkin LymphomaUnited States
-
Kolon TissueGene, Inc.Not yet recruiting
-
Asana BioSciencesCompletedDermatitis, Atopic | Pruritus | Dermatitis EczemaUnited States, Canada
-
TaiGen Biotechnology Co., Ltd.R&G Pharma Studies Co.,Ltd.Completed
-
TG Therapeutics, Inc.Completed
-
TG Therapeutics, Inc.Memorial Sloan Kettering Cancer CenterCompletedChronic Lymphocytic Leukemia | Richter SyndromeUnited States
-
TaiGen Biotechnology Co., Ltd.Completed
-
TaiGen Biotechnology Co., Ltd.R&G Pharma Studies Co.,Ltd.Completed